For decades antimonials were the drugs of choice for the treatment of visceral leishmaniasis
(VL), but the recent emergence of resistance has made them redundant as first-line therapy …

When citing, please refer to the published version. This is the peer reviewed accepted
manuscript of the following article: Or Page 1 This item was downloaded from IRIS Università di …

All currently used first-line and second-line drugs for the treatment of leishmaniasis exhibit
several drawbacks including toxicity, high costs and route of administration. Furthermore …

Visceral leishmaniasis (VL) is a chronic parasitic disease caused by the vector-borne
Leishmania donovani and Leishmania (L.) infantum chagasi parasites. The disease affects …

Autophagy is essential for cell survival under stress and has also been implicated in host
defense. Here, we investigated the interactions between Leishmania donovani, the main …

Leishmania (Viannia) braziliensis is the most common etiological agent of cutaneous and
mucocutaneous leishmaniasis (MCL) in Latin America. An interesting aspect of the disease …

Background Since miltefosine monotherapy against visceral leishmaniasis (VL) caused by
Leishmania donovani has been discontinued in the Indian subcontinent due to an increase …

Objectives Despite a continued search for novel antileishmanial drugs, treatment options
remain restricted to a few standard drugs, eg antimonials, miltefosine, amphotericin B and …

Background Visceral leishmaniasis is a disease caused by the protozoan Leishmania sp.
and is transmitted by Lutzomyia longipalpis (sand fly). In renal transplant recipients, visceral …

Introduction Leishmaniasis is a parasitic disease that affects more than 1 million people
worldwide annually, predominantly in resource-limited settings. The challenge in compound …